Business Context and Reporting Period
This Form 8-K Current Report was filed by CytomX Therapeutics, Inc. on March 23, 2020. The filing discloses the appointment of Carlos Campoy as Senior Vice President and Chief Financial Officer, effective immediately. Mr. Campoy also assumes the responsibilities of principal financial officer and principal accounting officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the leadership transition in the finance department. Mr. Campoy replaces the previous CFO, bringing experience from Alder BioPharmaceuticals, Think Forwards, Allergan plc, and Eli Lilly and Company.
Compensation and Employment Terms
- Base Salary: $465,000 annually.
- Annual Bonus Target: 40% of base salary.
- Signing Bonus: One-time payment of $150,000, subject to clawback provisions if employment is terminated for "cause" or resignation without "good reason" within the first two years.
- Stock Options: Grant of 350,000 shares under the 2019 Employment Inducement Incentive Plan. Vesting schedule includes 25% on the first anniversary and the remainder in equal monthly installments over 36 months.
- Indemnification: The Company will enter into a standard indemnification agreement covering legal expenses and judgments arising from his service as an executive officer.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 350,000 stock options once the grant is finalized.
- Review the full Employment Agreement and Indemnification Agreement when filed as exhibits to the Form 10-Q for the quarter ended March 31, 2020.
- Confirm the identity of the departing CFO and the reasons for the leadership change, which are not detailed in this specific filing.
- Monitor the Company's upcoming quarterly reports for the impact of the new CFO on financial reporting and strategic direction.